The discovery of a novel class of non-carbohydrate galectin-3 inhibitors without cytotoxicity shown in this study therefore not only offers great opportunities for therapeutic treatment of cancer but also of those diseases that are also in high unmet clinical needs. The gene discussed is LGALS3; the disease is cancer.